This CME activity will feature four HCV experts reviewing and discussing the most important studies presented on chronic hepatitis C at EASL. This review and discussion will provide unique insight into how knowledgeable experts review the key posters and presentations at EASL and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.
This program will enable all participating clinicians and health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.
This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HCV infection.
After completing this activity, participants should be able to:
Review clinically relevant posters and presentations on chronic hepatitis C made at the 46th EASL;
Explain to colleagues the clinical trials and data presented in the most important posters and presentations on chronic hepatitis C at the 46th EASL;
Discuss the scientific integrity and clinical relevance of the most important posters and presentations on chronic hepatitis C at the 46th EASL;
Use the information and data presented in the most important posters and presentations at the 46th EASL to improve patient care.
Release Date: April 11, 2011
Expiration Date: April 11, 2012
Estimated time to complete each Poster/Presentation: 15-30 minutes
Media: Internet
Douglas T. Dieterich, MD
Professor of Medicine and Director of CME,
Department of Medicine,
Director of Outpatient Hepatology,
Division of Liver Diseases,
Mount Sinai School of Medicine
New York, New York
Paul Y. Kwo, MD
Associate Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana
Jürgen Rockstroh, MD
Professor
University of Bonn
Bonn, Germany
Paul J. Pockros, MD
Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
The Scripps Clinic
La Jolla, California
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM per poster presentation. Physicians should claim only the credit commensurate with the extent of their participation in the activity
The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Dr. Douglas Dieterich:
Dr. Paul Kwo:
Dr. Paul Pockros:
Dr. Jurgen Rockstroh:
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
|
1. |
 |
The Pharmacokinetic Interaction between Methadone and the Investigational HCV PI Telaprevir |
|
2. |
 |
Once Daily Dual-Nucleotide Combination of PSI-938 And PSI-7977 Provides 94% HCV RNA |
| 3. |  |
Vitamin D Deficiency is Frequent in Chronic Hepatitis C and Affects the Outcome of Interferon-Alfa Based Therapy |
| 4. |  |
Once Daily Alisporivir (DEB025) Plus Pegifnalfa2a/Ribavirin Results in Superior Sustained Virologic Response (SVR24) in Chronic Hepatitis C Genotype 1 Treatment Naïve Patients |
| 5. |  |
First SVR Data with the Nucleoside Analogue Polymerase Inhibitor Mericitabine (RG7128) Combined with Peginterferon/Ribavirin in Treatment-Naive HCV G1/4 Patients: Interim Analysis from the Jump-C Trial |
| 6. |  |
Pegylated Interferon-Lambda (Pegifn-Λ) Shows Superior Viral Response with Improved Safety and Tolerability Versus Pegifnα-2a in HCV Patients (G1/2/3/4): Emerge Phase IIB Through Week 12 |
| 7. |  |
Quadruple Therapy with BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 Weeks Results in 100% SVR12 in HCV Genotype 1 Null Responders |
| 8. |  |
Il28b Polymorphism Predicts Virologic Response in Patients with Hepatitis C Genotype 1 Treated with Boceprevir (BOC) Combination Therapy |
| 9. |  |
Realize Trial Final Results: Telaprevir-Based Regimen for Genotype 1 Hepatitis C Virus Infection in Patients with Prior Null Response, Partial Response or Relapse to Peginterferon/Ribavirin |
| 10. |  |
SILEN-C2: Sustained Virologic Response (SVR) and Safety of BI201335 Combined with Peginterferon Alfa-2a and Ribavirin (P/R) in Chronic HCV Genotype-1 Patients with Non-Response to P/R |
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Supported by an educational grant from Merck & Co., Inc.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings
